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Abstract
Background: Undifferentiated high-grade pleomorphic sarcoma in gastrointestinal tract is extremely rare, and its
prognosis is poor.
Case presentation: An 82-year-old man visited a previous hospital complaining of fever, general fatigue, and shaking
chill, for which he received antibiotics therapy. As the fever continued, he was referred to our hospital, where computed
tomography and upper gastrointestinal endoscopy showed a 6-cm gastric tumor. A preoperative biopsy was consistent
with a malignant mesenchymal tumor, but could not provide a definitive pathological diagnosis nor prove a cause-and-
effect relationship between the chief complaint and the gastric tumor. The gastric tumor had grown to 8 cm in diameter
within a month so we performed a partial gastrectomy. The pathological postoperative diagnosis was undifferentiated
high-grade pleomorphic sarcoma that produced granulocyte colony-stimulating factor. The patient’s fever quickly
improved, and he showed a good postoperative course.
Conclusions: We herein report a case of rapidly growing, undifferentiated, high-grade pleomorphic gastric sarcoma,
which presented as a chief complaint of fever.
Keywords: Undifferentiated high-grade pleomorphic sarcoma, Stomach, Fever, Granulocyte colony-stimulating
factor (G-CSF)
Background
Undifferentiated high-grade pleomorphic sarcoma
(UPS) is a soft-tissue tumor usually found in the limbs
and in the retroperitoneum. Its prognosis is poor. Oc-
currence in gastrointestinal tract is extremely rare.
Here, we report a rare case of rapidly growing gastric
UPS associated with a persistent fever and discuss the
relevant literature.
Case presentation
An 82-year-old man presented at a nearby hospital with
fever, general fatigue, and shaking chill in July 2015.
Although he was treated with antibiotics for his high
level of c-reactive protein (CRP), his 38–39 °C fever
remained. He was therefore referred to our hospital.
When first examined, his body temperature was 38.4 °C
but had normal blood pressure and pulse rate. No ab-
normal palpable mass was reported. His blood examin-
ation findings showed high inflammatory reaction,
slightly low coagulability, and mildly activated fibrinoly-
sis. However, we observed no immunoglobulin or spe-
cific antibody that could be considered the cause of his
fever (Table 1). Abdominal computed tomography (CT)
in early August showed a 6-cm tumor in the stomach
(Fig. 1a) with an estimated volume of 18.07 ml. Neither
other tumor nor abscess was observed. Gastrointestinal
endoscopy (GIE) in early August showed a 6-cm pedun-
culated oval tumor on the upper part of the greater gas-
tric curvature (Fig. 2). We also found a nearby 2-cm* Correspondence: akaba@munakata-med-hp.gr.jp1Department of Surgery, Munakata Medical Association Hospital, 5-3-3
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sub-pedunculated oval tumor. They were elastic-hard,
with a smooth surface and a sparse ductal structure.
Biopsy specimen showed the proliferation of atypical
cells having pleomorphic or bizarre nuclei. Immunohis-
tochemically, some atypical cells were positive for c-kit,
alpha SMA, HHF-35, and calponin, but negative for
EMA, cytokeratin (CK) CAM5.2, DOG-1, CD34, caldes-
mon, and desmin. Although these findings were consist-
ent with malignant mesenchymal tumors, they did not
confirm the pathological diagnosis. Upper gastrointes-
tinal fluoroscopy in early August showed a 7-cm, multi-
nodular sub-pedunculated raised lesions with a 12-mm
attachment on the upper part of the greater gastric
curvature (Fig. 3). The 2-cm tumor observed in the GIE
was not visualized. In early September, a CT showed that
the gastric tumor had expanded to 8 cm in diameter
within the month, with the volume increased to
53.50 ml (Fig. 1b). The patient’s preoperative fever of
38 °C or higher, which was improved to 36 °C by taking
acetaminophen, occurred once or twice every day. But,
he had no symptoms such as abdominal pain and digest-
ive tract obstruction.
We considered that surgery to patients with fever was
dangerous, and we could not preoperatively confirm
pathological diagnosis of the tumor or its cause-and-
effect relationship to the main complaints. But, we fi-
nally chose to treat the tumor surgically because we
found no lesion that could have caused the fever, and we
were concerned that, if delayed, local resection of such a
rapidly growing tumor would become impossible.
In mid-September, we performed a partial gastrec-
tomy. We used laparoscopic assistance to disconnect the
Table 1 Patient’s clinical data
Blood count Blood chemistry Immune-
related tests
WBC 8300/μl TP 6.9 g/dl IgG 1683 mg/dl
RBC 384/μl Alb 3.0 g/dl IgA 243 mg/dl
Hb 10.8 g/dl GOT 18 U/l IgM 132 mg/dl
Ht 35.7% GPT 15 U/l Anti SS-A/Ro <7.0 U/ml
Plt 22.5 × 104/μl LDH 139 U/l Anti SS-B/La <7.0 U/ml
Clotting
factors
ALP 279 U/l β-D-glucan 7.5 pg/ml
PT 13.1 s γ-GTP 52 U/l MMP-3 84.3 ng/ml
PT-INR 1.23 BUN 15.2 mg/dl PR3-ANCA <1.0 U/ml
Fib 594.6 mg/dl Cr 0.91 mg/dl MPO-ANCA <1.0 U/ml
FDP 6.6 μg/ml AMY 60 U/l sIL-2R 411 U/ml
D-dimer 1.2 μg/ml Fe 44 mg/dl ANA <40 times
CRP 11.20 mg/dl Anti CCP <0.6 U/ml
Procalcitonin 0.07 ng/ml
RF <3 IU/ml
Fig. 1 Abdominal computed tomography (CT) showed a 6-cm gastric
tumor in early August (a) that had enlarged to 8 cm in diameter by
early September (b)
Fig. 2 Gastrointestinal endoscopy in early August showed a 6-cm
pedunculated tumor on the greater curvature in the gastric body (thick
arrow); nearby, a 2-cm sub-pedunculated tumor was also observed
(thin arrow)
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omentum from the cardia toward the gastric body to en-
sure mobility of the stomach. The upper stomach was
then lifted out of the abdominal wall through a 6-cm
incision in the left upper abdomen. A vertical incision
was added from the cardia to the gastric body in the
gastric anterior wall, through which both tumors were
pulled outside, and their roots excised from stomach
wall by automatic suturing devices (Endo-GIA with
Tri-Stapler, 30–2.5, Covidien), and then closed by
Albert–Lembert sutures.
Gross examination showed a pedunculated multinodu-
lar polypoid tumor (Fig. 4a) and a polypoid tumor
(Fig. 4b), measured about 8 × 5 × 3.5 and 2.2 × 1.5 × 1 cm
in size, respectively. Both tumors were solid-elastic
consistency, smooth surface, and covered with ulcerated
mucosa. The cut surface revealed the gray-white in color
with foci of hemorrhage. Microscopically, the resected
polypoid tumors were composed of atypical spindle cells
and large pleomorphic or bizarre tumor cells arranged
in sheets and irregular fascicles, associated with focal
hemorrhage and surface ulceration. Mitotic figures
(Fig. 5) including abnormal mitoses were frequently en-
countered (20–25/10 HPF). On immunohistochemical
examination, tumor cells were positive for vimentin, α1-
antichymotrypsin, CD68, CD163, G-CSF, p53, and Ki-67,
some tumor cells were positive for alpha SMA, HHF35,
and calponin, but tumor cells were negative for EMA,
CK AE1/AE3, CK CAM5.2, c-kit, CD34, DOG1, desmin,
a b
Fig. 3 Upper gastrointestinal fluoroscopy in early August showed a 7-cm sub-pedunculated raised lesion (a) with a 12-mm attachment (b) on the




Fig. 4 Gross findings of the tumors showed a pedunculated multinodular tumor (a) and a polypoid tumor (b). A gray-white tumor with focal hemorrhage
was observed by cut surface of the large one (c). The tumor was observed very close to the surgical margin
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caldesmon, S-100 protein, synaptophysin, hCG, HMB45,
myoglobin, and CD30. The histologic and immunohisto-
chemical features were consistent with undifferentiated
high-grade pleomorphic sarcoma (pleomorphic malig-
nant fibrous histiocytoma, UPS) producing granulocyte
colony-stimulating factor (G-CSF).
Although the patient had a 38 °C fever twice on 1–2
postoperative days (POD), no fever or other complica-
tions were observed thereafter. He began taking meals
on 5POD, and he was discharged with satisfactory pro-
gress on 12POD. Positron emission tomography (PET)/
CT examination on 1 month after surgery showed accu-
mulated fluoro-2-deoxy-D-glucose at the wound, but no
other abnormal accumulation.
Discussion
Malignant fibrous histiocytoma (MFH) has been classi-
fied into three subtypes: pleomorphic, inflammatory, and
giant cell. By the World Health Organization (WHO)
classification of bone and soft-tissue tumors of 2002,
pleomorphic-type MFH was defined as a synonym for
UPS [1]. Typically, UPS forms a large, rapidly growing
solid mass and is histologically characterized by pleo-
morphic tumor cells in storiform patterns. UPS does not
tend to show clear differentiation and has no specific
immunohistological marker [1, 2]. Although UPS was
defined in 2002, its epidemiology and prognosis has ob-
scured because of its rarity. In reports of MFH, it com-
monly occurs in men and those older than 40 years,
with a frequency of 1–2 cases per 100,000 people
[3].MFH has been reported in limbs (68%), abdominal
cavity/retroperitoneum (16%), trunk (9%), head and neck
(3%), or gastrointestinal tract (4%). Its prognosis is poor,
with a repoted 2-year survival rate of 60%, and a 5-year
survival rate of 47% [3].
Primary gastric UPS or MFH is quite rare. Saito et al.
reported 16 case reports of primary UPS or MFH of
stomach, including one they reported and 14 found in
PubMed using the keywords “undifferentiated pleo-




Fig. 5 Microscopic findings showed proliferation of atypical spindle-shaped tumor cells arranged in sheets and irregular fascicles (a). Mitotic figures were
frequently encountered (arrows, 20–25/10 HPF) and mild infiltration of lymphoplasmacytoid cells was noted (b). The large pleomorphic and bizarre tumor
cells were also observed (c). Immunohistochemically, the tumor cells were positive for α1-antichymotrypsin (d), p-53 (e), and G-CSF (f)
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during 1984–2011 [4–16]. The data of 16 cases and this
case are summarized in Table 2. The average age was
about 61 years old (range: 17–82 years old). Average
diameter was 6.7 cm (range: 1–15 cm). Seven of the 16
patients showed invasion or metastasis and had died by
the time they were reported. Only 4 of the 16 patients
were 2-year survivors at the time they were reported. No
5-year survivors were yet reported. UPS is considered to
have worse prognosis than other forms of MFH. In
addition, there has been no report about gastric UPS
producing G-CSF.
According to the National Comprehensive Cancer
Network (NCCN) Soft Tissue Sarcoma Guidelines, sur-
gical resection with sufficient margin is the first-choice
treatment for UPS. Amputation is required for tumors
in limbs, so various surgical methods have been used
with the aim of preserving function [17]. The first choice
for resectable sarcomas in the inner trunk is considered
to be en bloc excisions with ≥1-cm margins. Additional
resection is recommended for margins narrower than
1 cm. As lymphatic metastasis is rare, systematic lymph
node resection is not required. If hepatic metastases or
infiltrations to nearby organs are resectable, their
complete resection is desirable. Chemotherapy, radiation
therapy, or hyperthermia have been used for unresect-
able tumors. The combination of cisplatin, ifosfamide,
and adriamycin for reducing metastasis has been re-
ported [18]. However, chemotherapy, radiation ther-
apy, and hyperthermia have not led to satisfactory
results [19, 20].
At first we suspected that infection or autoimmune
diseases could have caused the fever and high CRP level;
we had doubts about their association with the gastric
tumor. However, as the fever and CRP level dramatically
improved after the surgery, the gastric tumors were
clearly related to the main complaints. There are reports
about cases of UPS and MFH presenting initially with
fever [21–23], and reports about cases of MFH produ-
cing actively cytokines such as G-CSF [24–27]. But. this
is the first report about gastric UPS with fever and rapid
growth due to producing G-CSF. G-CSF is thought to
cause paraneoplastic syndrome such as fever or in-
creased CRP, and cytokines such as G-CSF have been
suggested as markers for UPS. In this case, we should re-
flect that treatment was delayed because we could not
understand that these symptoms could be a clue to the
diagnosis.
Conclusions
We found a rare case of gastric UPS. As UPS is a rapidly
growing, frequently recurring tumor, its prognosis is
poor. Patients require strict postoperative observation.
Table 2 Summarization in 16 cases diagnosed primary gastric UPS and MFH
No. Year Author Age Gender Chief
complaint
Site Macroscopic forms Size (cm) Metastasis or
invasion
Therapy Outcome
1 1984 Morita 60 F Pain Antrum SMT 3.5 Gall bladder Operation,
hemotherapy
Death, 6POM
2 1985 Shibuya 60 M Bleeding Antrum Raised type 4.5 Ileum Operation Death, 3POM
3 1985 Randner 77 F Pain Body SMT 1 Liver None Death
4 1988 Wright 42 M Bleeding Cardia Ulcerative type 5 Lung Operation,
chemotherapy
Death, 17POM
5 1989 Ranthakrishman 51 M Pain Antrum Tube-occupied type Huge None Operation
(stoma)
Death, 0.5POM
6 1998 Takagi 64 T Amenia Body SMT 7.5 None Operation Alive, 6POM
7 1998 Wada 78 M Pain Body Ulcerative type 5 None Operation Alive, 24POM
8 1998 Wada 77 M Pain Body Ulcerative type 4 Lung Operation Death, 48POM
9 1998 Wierseme 37 F Amenia Body Ulcerative type 5 None Operation Alive, 38POM
10 2000 Nakai 57 M Pain Antrum Tube-occupied type 5 Liver Operation,
chemotherapy
Death, 7POM
11 2003 Accattatis 17 F Pain Body Unknown 15 None Operation Death, 0.5POM
12 2006 Shinnshi 54 M Pain Antrum SMT 4 None Operation Alive, 36POM
13 2007 Agaimy 79 M None Cardia Ulcerative type 8 None Operation Death, 0.5POM
14 2007 Agaimy 68 F Weight loss Body Extraluminal growth
type
12 None Operation Alive, 6POM
15 2013 Kinoshita 74 F Pain body Raised type 13 Liver Chemotherapy Death
16 2016 This case 82 M Fever Body Raised type 8 None Operation Alive
POM postoperative months
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